| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082522 | Drug Discovery Today: Technologies | 2013 | 8 Pages |
Abstract
Allosteric modulation has emerged as an innovative pharmacological approach to selectively activate or inhibit several Class C GPCRs. Of the Class C GPCRs, metabotropic glutamate (mGlu) receptors represent the most promising candidates for clinical success, and both positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) of mGluRs have demonstrated therapeutic potential for a range of psychiatric and neurological disorders such as pain, depression, anxiety, cognition, Fragile X syndrome, Parkinson's disease and schizophrenia.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Darren W. Engers, Craig W. Lindsley,